Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D W Hay

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
American Journal of Physiology. Lung Cellular and Molecular Physiology|October 29, 2000
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lungD C Underwood, R R Osborn, S Bochnowicz, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1987
Pharmacologic profile of SK&F 104353, a novel, highly potent and selective peptidoleukotriene antagonistM A Wasserman, T J Torphy, D W Hay, et al.
Pulmonary Pharmacology|January 1, 1991
Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pigD W Hay, R M Muccitelli, L M Vickery-Clark, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1995
Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthmaM C Chabot-Fletcher, D C Underwood, J J Breton, et al.
Journal of Medicinal Chemistry|June 7, 1996
2-Phenyl-4-quinolinecarboxamides: a novel class of potent and selective non-peptide competitive antagonists for the human neurokinin-3 receptorG A Giardina, H M Sarau, C Farina, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 29, 2000
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistenceD C Underwood, R R Osborn, C J Kotzer, et al.
Genes and Immunity|October 26, 2007
Polymorphisms in the endothelin-1 (EDN1) are associated with asthma in two populationsG Zhu, K Carlsen, K-H Carlsen, et al.
Journal of Medicinal Chemistry|March 26, 1999
Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412)G A Giardina, L F Raveglia, M Grugni, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1997
Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonistH M Sarau, D E Griswold, W Potts, et al.
European Journal of Pharmacology|February 28, 2001
Molecular and pharmacological characterization of the murine tachykinin NK(3) receptorH M Sarau, J A Feild, R S Ames, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
American Journal of Physiology. Lung Cellular and Molecular Physiology|October 29, 2000
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lungD C Underwood, R R Osborn, S Bochnowicz, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1987
Pharmacologic profile of SK&F 104353, a novel, highly potent and selective peptidoleukotriene antagonistM A Wasserman, T J Torphy, D W Hay, et al.
Pulmonary Pharmacology|January 1, 1991
Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pigD W Hay, R M Muccitelli, L M Vickery-Clark, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1995
Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthmaM C Chabot-Fletcher, D C Underwood, J J Breton, et al.
Journal of Medicinal Chemistry|June 7, 1996
2-Phenyl-4-quinolinecarboxamides: a novel class of potent and selective non-peptide competitive antagonists for the human neurokinin-3 receptorG A Giardina, H M Sarau, C Farina, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 29, 2000
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistenceD C Underwood, R R Osborn, C J Kotzer, et al.
Genes and Immunity|October 26, 2007
Polymorphisms in the endothelin-1 (EDN1) are associated with asthma in two populationsG Zhu, K Carlsen, K-H Carlsen, et al.
Journal of Medicinal Chemistry|March 26, 1999
Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412)G A Giardina, L F Raveglia, M Grugni, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1997
Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonistH M Sarau, D E Griswold, W Potts, et al.
European Journal of Pharmacology|February 28, 2001
Molecular and pharmacological characterization of the murine tachykinin NK(3) receptorH M Sarau, J A Feild, R S Ames, et al.
Pageof 12